Business News • PR NewsWire • NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

AMSTERDAM, April 22, 2017 /PRNewswire/ -- NGM Bio announced that its lead product candidate, NGM282, met the primary endpoint and key secondary endpoints in a Phase 2 trial of patients with nonalcoholic steatohepatitis (NASH). NGM282, which is a non-tumorigenic, engineered variant of the...

View More : http://www.prnewswire.com/news-releases/ngm-bio-announces-ngm282-dramatically-reduced-liver-fat-and-other-biomarkers-ass...

Releted News by prnewswire

Los Premios Edison otorgan un reconocimiento a Ortho Clinical Diagnostics por el excepcional grado de innovación de sus productos

IBM Study: Four Ways to Achieve Maximum ROI in Enterprise Mobility

Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis